Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Safety, Tolerability and Antiviral Activity of 12 Weeks' Treatment With a New Antiviral HCMV Drug
Conditions
Interventions
60 mg AIC246
120 mg AIC246
+2 more
Locations
24
United States
UCLA Medical Center
Los Angeles, California, United States
Stanford University Hospital
Stanford, California, United States
Denver St. Lukes Presbyterian
Denver, Colorado, United States
University of Florida
Gainesville, Florida, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Loyola University Chicago
Maywood, Illinois, United States
Start Date
March 1, 2010
Primary Completion Date
October 1, 2011
Completion Date
December 1, 2011
Last Updated
February 13, 2018
Lead Sponsor
AiCuris Anti-infective Cures AG
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions